Abstract

PurposeMeasurement of the second virial coefficient B22 for proteins using self-interaction chromatography (SIC) is becoming an increasingly important technique for studying their solution behaviour. In common with all physicochemical chromatographic methods, measuring the dead volume of the SIC packed column is crucial for accurate retention data; this paper examines best practise for dead volume determination.MethodSIC type experiments using catalase, BSA, lysozyme and a mAb as model systems are reported, as well as a number of dead column measurements.ResultsIt was observed that lysozyme and mAb interacted specifically with Toyopearl AF-Formyl dead columns depending upon pH and [NaCl], invalidating their dead volume usage. Toyopearl AF-Amino packed dead columns showed no such problems and acted as suitable dead columns without any solution condition dependency. Dead volume determinations using dextran MW standards with protein immobilised SIC columns provided dead volume estimates close to those obtained using Toyopearl AF-Amino dead columns.ConclusionIt is concluded that specific interactions between proteins, including mAbs, and select SIC support phases can compromise the use of some standard approaches for estimating the dead volume of SIC columns. Two other methods were shown to provide good estimates for the dead volume.

Highlights

  • Monoclonal antibodies have successfully been used in clinical trials for treatments of several cancer and autoimmune diseases [1,2,3] and have lately become the fastest growing segment of the biopharmaceutical industry [4, 5]

  • The current understanding about the way Monoclonal antibodies (mAbs) behave in different solution conditions, and the the effects of solution conditions on formulation stability is still not fully understood, especially in terms of the mechanisms leading to aggregation and their long-term aggregation stability [9, 10]

  • Therapeutic proteins such as mAbs have complex structures and often have relatively large molecular sizes, so when they are exposed to certain solution conditions they are prone

Read more

Summary

Introduction

Monoclonal antibodies (mAbs) have successfully been used in clinical trials for treatments of several cancer and autoimmune diseases [1,2,3] and have lately become the fastest growing segment of the biopharmaceutical industry [4, 5]. The current understanding about the way mAbs behave in different solution conditions, and the the effects of solution conditions on formulation stability is still not fully understood, especially in terms of the mechanisms leading to aggregation and their long-term aggregation stability [9, 10]. Therapeutic proteins such as mAbs have complex structures and often have relatively large molecular sizes, so when they are exposed to certain solution conditions they are prone

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call